Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 13 of 13 entries
View as:

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00261677 Org: User:
Start: 08/31/00 End: 10/31/03 Due: 10/31/04

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00495378 Org: User:
Start: 11/30/02 End: 03/31/03 Due: 03/31/04

Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00315484 Org: User:
Start: 02/28/03 End: 10/31/04 Due: 10/31/05

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00123149 Org: User:
Start: - End: 10/31/07 Due: 10/31/08

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Phase: N/A Priority: Normal
NCT ID: NCT00338468 Org: User:
Start: 11/30/03 End: 09/30/05 Due: 09/30/06

Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00212862 Org: User:
Start: 12/31/03 End: 07/31/09 Due: 07/31/10

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Phase: N/A Priority: Normal
NCT ID: NCT00307814 Org: User:
Start: 01/31/02 End: 01/31/04 Due: 01/31/05

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

Phase: N/A Priority: Normal
NCT ID: NCT00317902 Org: User:
Start: 10/31/02 End: 05/31/04 Due: 05/31/05

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00246597 Org: User:
Start: 12/31/02 End: 06/30/04 Due: 06/30/05

A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00495365 Org: User:
Start: 06/30/03 End: 09/30/03 Due: 09/30/04

NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection

Phase: N/A Priority: Normal
NCT ID: NCT00315432 Org: User:
Start: 09/30/00 End: 11/30/03 Due: 11/30/04

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Phase: N/A Priority: Normal
NCT ID: NCT00328549 Org: User:
Start: 10/31/01 End: 12/31/02 Due: 12/31/03

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT00350090 Org: User:
Start: 09/30/02 End: 03/31/04 Due: 03/31/05